Retatrutide, a experimental dual agonist of the GLP-1 target and glucose-dependent secreted polypeptide (GIP) target, is demonstrating promising results in initial human assessments . Current inquiry https://businessbookmark.com/story6933736/retatrutide-emerging-investigations-and-potential-clinical-roles